Results 11 to 20 of about 411,751 (361)

A Toll for lupus [PDF]

open access: yes, 2005
Toll-like receptor (TLR)-9 recognizes CpG motifs in microbial DNA. TLR9 signalling stimulates innate antimicrobial immunity and modulates adaptive immune responses including autoimmunity against chromatin, e.g., in systemic lupus erythematosus (SLE ...
Anders, Hans-Joachim, H-J Anders
core   +1 more source

Joint involvement in patients affected by systemic lupus erythematosus: application of the swollen to tender joint count ratio

open access: yesReumatismo, 2015
Joint involvement is a common manifestation in systemic lupus erythematosus (SLE). According to the SLE disease activity index 2000 (SLEDAI-2K), joint involvement is present in case of ≥2 joints with pain and signs of inflammation.
E. Cipriano   +7 more
doaj   +1 more source

Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. [PDF]

open access: yes, 2011
The long pentraxin PTX3 has multiple roles in innate immunity. For example, PTX3 regulates C1q binding to pathogens and dead cells and regulates their uptake by phagocytes. It also inhibits P-selectin-mediated recruitment of leukocytes.
Mantovani Alberto   +32 more
core   +1 more source

Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus

open access: yesArthritis Research & Therapy, 2018
Background The application of more sensitive imaging techniques, such as ultrasonography (US), changed the concept of non-erosive arthritis in systemic lupus erythematosus (SLE), underlining the need for biomarkers to identify patients developing the ...
Fulvia Ceccarelli   +11 more
doaj   +1 more source

Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus

open access: yesACR Open Rheumatology, 2021
Objectives Patients with systemic lupus erythematosus (SLE) are usually treated with glucocorticosteroids even during periods of clinically quiescent disease.
Konstantinos Tselios   +3 more
doaj   +1 more source

Lupus nephritis and lupus band test [PDF]

open access: yesPostgraduate Medical Journal, 1981
Summary Twenty-seven patients with histologically confirmed lupus nephritis were studied to identify the incidence of lupus band and its significance to histological patterns of nephritis and complement levels. It was found that the kidney involvement is 2.5 times more frequent in lupus band positive patients.
B A, Adam   +3 more
openaire   +2 more sources

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

open access: yesTrials, 2023
Background Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms.
Mark E. McClure   +13 more
doaj   +1 more source

Kidney disease in lupus is not always 'lupus nephritis' [PDF]

open access: yesArthritis Research & Therapy, 2013
In lupus erythematosus, elevated serum creatinine levels and urinary abnormalities implicate a kidney disorder, which may not always be lupus nephritis as defined by the current classification of the International Society of Nephrology/Renal Pathology Society.
Anders, Hans-Joachim, Weening, Jan J.
openaire   +3 more sources

Early Discoid Lupus Erythematosus Protects Against Renal Disease In Patients With Systemic Lupus Erythematosus: Longitudinal Data From A Large Latin American Cohort

open access: yes, 2017
The objective of this study was to examine whether early discoid lupus erythematosus (DLE) would be a protective factor for further lupus nephritis in patients with systemic lupus erythematosus (SLE).
V.; Alvarellos   +19 more
core   +3 more sources

New efforts to incorporate patient-reported outcomes into lupus clinical trials: report of the community meeting convened by the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), 16–17 October 2024

open access: yesLupus Science and Medicine
The Lupus Research Alliance formed the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) in 2023 as a public-private partnership with investigators, pharmaceutical companies, the Food and Drug Administration, National Institutes of Health, patient ...
  +28 more
doaj   +1 more source

Home - About - Disclaimer - Privacy